Core Scientific (CORZ) Cash from Financing Activities (2021 - 2026)

Core Scientific (CORZ) has 6 years of Cash from Financing Activities data on file, last reported at $971.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 23239.16% year-over-year to $971.4 million; the trailing twelve-month figure through Mar 2026 stood at $912.5 million (up 19.9% YoY), and the FY2025 full-year result was -$63.1 million, down 107.7% from the prior year.
• Cash from Financing Activities improved to $971.4 million in Q1 2026, from -$21.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $971.4 million in Q1 2026 to a low of -$45.1 million in Q3 2022.
• A 5-year average of $117.0 million and a median of -$4.2 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 148.04% in 2023 and jumped 23239.16% in 2026, its largest moves.
• Tracing CORZ's Cash from Financing Activities over 5 years: stood at $38.1 million in 2022, then plunged by 148.04% to -$18.3 million in 2023, then soared by 3369.23% to $598.2 million in 2024, then sank by 103.65% to -$21.8 million in 2025, then jumped by 4554.25% to $971.4 million in 2026.
• Business Quant data shows CORZ's Cash from Financing Activities at $971.4 million in Q1 2026, -$21.8 million in Q4 2025, and -$5.3 million in Q3 2025.